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ABSTRACT: Protein and phosphoinositide kinases have been
successfully exploited as drug targets in various disease areas,
principally in oncology. In malaria, several protein kinases are
under investigation as potential drug targets, and an inhibitor of
Plasmodium phosphatidylinositol 4-kinase type III beta (PI4KIIIβ)
is currently in phase 2 clinical studies. In this Perspective, we
review the potential of kinases as drug targets for the treatment of
malaria. Kinases are known to be readily druggable, and many are
essential for parasite survival. A key challenge in the design of
Plasmodium kinase inhibitors is obtaining selectivity over the
corresponding human orthologue(s) and other human kinases due to the highly conserved nature of the shared ATP binding site.
Notwithstanding this, there are some notable differences between the Plasmodium and human kinome that may be exploitable. There
is also the potential for designed polypharmacology, where several Plasmodium kinases are inhibited by the same drug. Prior to
starting the drug discovery process, it is important to carefully assess potential kinase targets to ensure that the inhibition of the
desired kinase will kill the parasites in the required life-cycle stages with a sufficiently fast rate of kill. Here, we highlight key target
attributes and experimental approaches to consider and summarize the progress that has been made targeting Plasmodium PI4KIIIβ,
cGMP-dependent protein kinase, and cyclin-dependent-like kinase 3.
KEYWORDS: Plasmodium, protein kinase, lipid kinase, target validation, malaria, drug discovery
Malaria in humans, caused by five species of Plasmodium,is still a massive problem in many parts of the world,
causing approximately 228 million clinical cases and 405,000
deaths in 2018, mainly among children under 5 and pregnant
women in sub-Saharan Africa.1,2 In addition to active cases,
there are likely to be significant numbers of asymptomatic
carriers.3 The most severe form of malaria results from
infection with P. falciparum. The other predominant strain
causing human disease is P. vivax, which causes a relapsing
form of the disease. Human disease is also caused by P. ovale,
P. malariae, and P. knowlesi. Control and ultimate elimination
of malaria is likely to require the application of multiple
different strategies, including the use of insecticide-impreg-
nated bed nets, appropriate drug therapies, and vector control
through the use of insecticides and vaccines. Despite significant
progress in reducing the incidence of the disease and
associated deaths, this seems to have plateaued in recent
years.4 Undoubtedly, there are multiple reasons for this,
including emerging resistance to current drugs within the
parasite population as well as resistance to commonly used
insecticides within the mosquito vector population. Of
particular concern is the reported increase in resistance to
artemisinin, a core component of current front-line artemisinin
combination therapies (ACTs), in South East Asia. There is
growing fear that resistance to artemisinin-based therapies will
spread to other areas, thus threatening the effectiveness of this
mainstay therapy. Indeed, a recent study from Uwimana and
colleagues demonstrated that P. falciparum samples isolated
from patients in Rwanda were resistant to artemisinin in vitro,
the first report of this type from Africa.5 In addition to new
drugs to tackle the problem of drug resistance, there is an
urgent need for new drug classes with novel mechanisms of
action to aid the elimination and/or eradication agenda:
chemoprotection, especially important for vulnerable groups in
areas of low transmission and where malaria is seasonal;
transmission-blocking agents to remove gametocytes from the
blood, thus blocking transmission; a radical cure for P. vivax
malaria.
New medicines for malaria are developed as combination
therapies in order to slow the emergence of resistance and to
improve clinical efficacy. Medicines for Malaria Venture
Received: October 15, 2020
Perspectivepubs.acs.org/journal/aidcbc




ACS Infect. Dis. XXXX, XXX, XXX−XXX
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,






















































































(MMV) has developed the following Target Product Prof iles
(TPPs) for malaria.6
• TPP-1 case management: Treatment of acute uncom-
plicated malaria, relapsing malaria, and severe malaria,
including population-based strategies such as the
treatment of asymptomatic infections and transmission
blocking
• TPP-2 chemoprotection: For outbreak prevention and
use in subjects migrating to endemic areas
These are used to derive Target Compound Prof iles (TCPs),
outlining the properties required in an individual molecule.
These include in vitro and in vivo activity, physicochemical,
pharmacokinetic, and safety pharmacology properties. The
TCPs include the following:
• TCP1: Molecules that clear asexual blood-stage parasites
to cure blood-stage malaria
• TCP3: Molecules active against hypnozoites to provide a
radical cure of P. vivax malaria
• TCP4: Molecules active against liver schizonts to
provide chemoprotection
• TCP5: Molecules active against gametocytes to block
transmission
• TCP6: Molecules that target the mosquito to block
transmission
Up until now, most compounds developed for malaria have
been identified phenotypically.7 However, there is increasing
interest in target-based drug discovery for malaria. It is
important that when selecting a drug target the inhibitors of
this molecular target are capable of satisfying at least one of the
TCPs.
One class of molecular drug targets that has been extensively
investigated in multiple disease areas, in particular oncology, is
kinases, both protein and lipid. Currently, an inhibitor of the
human malaria parasite Plasmodium falciparum phosphatidyli-
nositol 4-kinase type III beta (PfPI4KIIIβ) is in the clinical
development for malaria,8,9 identifying PfPI4KIIIβ as an
exciting, exploitable molecular target. In this Perspective, we
assess kinases as potential antimalarial drug targets and discuss
the challenges associated with developing drugs that
specifically inhibit these enzymes. Here, we focus on protein
and phosphoinositide kinases (PIKs). For information related
to other kinases, such as choline kinase10,11 and hexokinase
(glucokinase), a reference is made to the specific literature.12,13
In addition, a recent review from Cabrera and colleagues deals
with Plasmodium kinases as drug targets and specific classes of
inhibitors.14
Protein and phosphoinositide kinases represent attractive
drug targets for multiple reasons. In general, kinases are readily
druggable; there is a huge knowledge base to help guide the
development of specific kinase inhibitors, and multiple kinase-
focused compound libraries are available for screening to
provide starting points for drug discovery. There is also
significant structural information available to support the
design and optimization of inhibitors.
Protein kinases have a plethora of physiological roles within
cells ranging from signal transduction to cell fate control. At
the most basic level, these enzymes catalyze the transfer of γ-
phosphate from ATP (or GTP) to protein substrates, most
commonly at the site of serine, threonine, or tyrosine residues.
In comparison to mammalian kinases, the understanding of the
physiological roles of Plasmodium kinases and their substrates
is in its infancy. The improvement of the understanding of the
specific and possibly unique functions of Plasmodium kinases
will be crucial in facilitating the full exploitation of this enzyme
class for antimalarial drug discovery.
Figure 1. Overview of the P. falciparum17 and human23 kinomes. Eukaryotic protein kinase (ePK) groups include AGC (named after protein kinase
A, G, and C families, containing cyclic nucleotide and calcium/phospholipid-dependent kinases), CAMK (calmodulin/calcium-dependent kinase),
CK1 (casein or cell kinase 1), CMGC (named after CDK, MAPK, GSK3, and CLK families), STE (homologues of yeast STE7, STE11, and STE20
genes, including kinases in MAPK pathways but not MAPKs), TK (tyrosine kinase), TKL (tyrosine kinase-like serine/threonine kinase), RGC
(receptor guanylate cyclase), and other (other protein kinases including the NEK (never in mitosis A (NIMA)-related kinase) family). The
apicomplexan specific ePK-related kinase family FIKK (Phe (F)−Ile (I)−Lys (K)−Lys (K)) consists of 19 members, of which 18 are specific to
P. falciparum and closely related species. Atypical protein kinases (aPKs) include PIKKs (phosphatidylinositol 3-kinase-related kinases, all three of
which are classified as PIKs in the section below) and RIO (right open reading frame) families in Plasmodium.
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■ THE PLASMODIUM KINOME
The Plasmodium kinome consists of between 60 and 90 protein
kinases, depending on the species and the stringency of the
classification method, with kinases accounting for ∼1.7% of
coding genes within P. falciparum.15−17 While many of these
kinases can be classified into one of the established eukaryotic
protein kinase (ePK) groups (AGC, CAMK, CK1, CMGC,
STE, TKL, or other; see the Figure 1 legend for definitions of
the different kinase groups in this paragraph) or atypical kinase
(aPK) groups (PIKK and RIO), the Plasmodium kinome
displays significant genetic divergence from the kinomes of
other eukaryotes and importantly from its human host (Figure
1). Many Plasmodium kinases have no clear human orthologue,
and in cases where orthologues exist, atypical features and
significant structural differences are often apparent. These
typically include large insertions within kinase domains as well
as pronounced differences in regulatory regions, suggesting
that the regulatory mechanisms and functions of these kinases
may differ substantially from their human orthologs. Unique
features that distinguish the Plasmodium kinome from the
human kinome include: (1) the absence of tyrosine kinases
(TK), the largest kinase group in humans, and the structurally
related receptor guanylate cyclases (RGCs); (2) no clearly
recognizable MAPKK homologue, despite the presence of two
MAPKs; (3) the CAMK group, which includes a 7-member
family of calcium-dependent protein kinases (CDPKs) also
found in plants and other protists,18 for which there are no
mammalian orthologues; (4) the presence of FIKKs, an ePK-
related family unique to apicomplexan parasites.15,19 The
kinome is largely conserved between Plasmodium species,
although the exact numbers of kinases within a given group can
vary, suggesting possibly divergent roles and/or redundancy.
On the basis of the analysis by Miranda-Saavedra et al.,17 the
kinome of the most virulent species, P. falciparum, consists of
65 ePKs, 5 aPKs, and 19 FIKKs (Figure 1). This is
substantially larger than the kinomes of other Plasmodium
species, principally due to an expansion of the FIKK family in
P. falciparum to 19 members while other Plasmodium species
maintain only one. All 18 of these unique FIKKs have export
signal sequences and are thought to play specific roles in
virulence through the modulation of host factors.20−22 A recent
quantitative phosphoproteomics study by Davies et al. showed
unique phosphorylation patterns for P. falciparum FIKK
kinases, including FIKK-dependent phosphorylation of parasite
virulence factors and host erythrocyte proteins.22
■ PLASMODIUM PHOSPHOINOSITIDE KINASES
Lipid phosphoinositides are universal signaling molecules that
play fundamental roles in almost all aspects of cellular function
including growth, cell division, organelle identity, and
membrane trafficking.24 Different phosphoinositide species
are generated by the highly regulated activity of lipid PIKs and
phosphatases.25,26 PIKs are named according to the
phosphoinositide product they generate, and kinases with
different evolutionary paths have converged to produce the
same phosphoinositide species.25 The human genome encodes
for 19 PIKs that can be clustered into three groups based on
structural similarity (Figure 2A).25,27 Dysregulation of human
PIKs, particularly phosphoinositide 3-kinases (PI3Ks), has
been associated with a variety of human diseases including
cancer and immunodeficiency disorders (review by Burke25).
In addition, human PIKs are important host enzymes that are
hijacked by pathogens in order to mediate viral replication and
bacterial infections. Consequently, concerted efforts have been
made to exploit PIKs for drug discovery. These efforts have
predominantly focused on PI3K and PI4K enzymes; in
comparison, less is known about phosphatidylinositol
phosphate kinases (PIPKs).
The P. falciparum genome encodes 7 putative PIKs (Figure
2B).28 Even though P. falciparum PI4KIIIβ (PF3D7_0509800)
is a clinically validated drug target for malaria,8,9 the role of the
other PIKs in Plasmodium and their potential as drug targets
are largely unexplored. Although interest in targeting PfPI3K
(PF3D7_0515300, also referred to as PfVps34) has been
expressed, genetic essentiality demonstrated,29,30 and human
PI3K inhibitors with potent in vitro PfPI3K and antiplasmo-
Figure 2. Overview of human and Plasmodium phosphoinositide kinases (PIKs) and their putative substates. (A) Human PIKs and substrates
clustered into 3 groups based on structure similarity.25 (B) Plasmodium PIKs/PIK-related proteins and substrates. Proteins are labeled using
PlasmoDB (https://plasmodb.org/) gene indentifiers for the P. falciparum 3D7 strain. Putative PIKs that have not yet been studied are enclosed by
dotted lines (PF3D7_0419900, PF3D7_0311300, PF3D7_1129600, PF3D7_1412400). Proteins are colored to match the human PIK(s) that they
most closely resemble on the basis of sequence similarity according to Hassett and Roepe,28 and their proposed substrates are indicated.29,37
Genetic essentiality is indicated according to available data in the PhenoPlasm database (http://phenoplasm.org/) on the basis of gene disruption
studies performed in P. falciparum 3D7 (piggyBac insertion mutagenesis)30 and in P. berghei ANKA (PlasmoGem/RMgmDB): tick (checkmark),
essential; cross (X), nonessential; question mark (?), conflicting data between studies.
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dium activity identified,31,32 to our knowledge, no major
medicinal chemistry programs targeting this Plasmodium
enzyme have been reported to date. As is the case for PI3K
class III enzymes in other organisms, PfPI3K is thought to play
a role in the regulation of autophagy.33 In addition, PfPI3K has
been shown to play a role in hemoglobin endocytosis and
trafficking and has been controversially implicated in PfKelch-
13-mediated artemisinin resistance.34−36
■ KEY STRUCTURAL FEATURES OF KINASES
Over five thousand unique high-resolution structures of kinase
domains, including protein and related kinases that act on
nonprotein substrates such as PIKs, have been deposited in the
Protein Data Base (PDB). The three-dimensional structure of
the kinase domains is highly conserved, and key features of
ePKs have been well described.38−40 Despite low sequence
conservation, ePKs, aPKs, and PIKs share a similar three-
dimensional kinase fold and many other of the key structural
features.41 High-resolution structures of at least 11 different
Plasmodium protein kinases have been solved (PbCDPK1
(3Q5I), PfCDPK2 (4MVF), PfCDPK4 (4QOX, 4RGJ),
PfCK2 (5XVU),42 PfCLK1 (3LLT), PfMAPK2 (3NIE),
PbMAPK2 (3N9X), PfPK5 (e.g., 1OB3),43 PfPK7 (e.g.,
2PMN),44 PfPKG (5DYK),45 and PvPKG (e.g., 5DZC).45
Recently, structures of P. falciparum choline kinase (PfChoK)
and hexokinase have also been reported.11,13 To our
knowledge, no Plasmodium PIK structures have been
elucidated to date.
The key features of the conserved ePK domain are
illustrated in Figure 3 using a high-resolution structure of the
kinase domain of Plasmodium vivax cGMP-dependent protein
kinase (PvPKG) as an example.45 The ATP binding site is
situated between the small N-terminal lobe, made up of a five-
stranded β-sheet (β1−β5) and the catalytic αC-helix, and the
larger α-helical-rich C-terminal lobe.46 The hinge region
connects the two lobes and contains a conserved valine that
interacts with adenine of ATP as well as the so-called hinge-
binding motif of small molecule ATP-competitive kinase
inhibitors via “donor−acceptor−donor” interactions. The
gatekeeper residue (PvPKG Thr611) is situated at the end of
β5 before the hinge region. The size of the gatekeeper residue
affects the accessibility to a small pocket adjoining the ATP
binding site, typically referred to as the back pocket. Small
molecule kinase inhibitors, referred to as bumped-kinase
inhibitors, that selectively target enzymes with small gatekeeper
residues (Thr/Ser) can extend into this back pocket.47,48 A
glycine-rich loop in ePKs situated between β1 and β2,
commonly referred to as the phosphate binding loop (P-
loop), acts as a lid over the phosphate channel, securing the
ATP in position. The P-loop is also present in the aPKs and
PIKs, serving an analogous function; however, the glycine-rich
sequence motif (GxGxxG) is not conserved. The P-loop is
followed by a conserved valine residue (PvPKG Val548) that
Figure 3. Key conserved features of the kinase domain and ATP binding site. (A) Overview of the PvPKG kinase domain and (B) enlarged view of
the ATP binding site. Key features are indicated as follows: N-terminal lobe in pale green; C-terminal lobe in gray; hinge region in red; P-loop in
blue; AxK motif within β3 in purple; catalytic αC-helix in cyan; activation segment with the DFG motif, phosphorylation site (Thr688), and APE
motif in yellow; catalytic loop with the YRD motif in magenta; ATP analogue (phosphoaminophosphonic acid−adenylate ester) bound within the
ATP binding site in bright green (PDB ID: 5DZC). (C) Two-dimensional schematic of ATP binding site showing “donor−acceptor−donor”
interactions with the hinge residues observed for ATP and typical small molecule ATP-competitive inhibitors.
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forms hydrophobic interactions with the adenine of ATP and
many ATP-competitive inhibitors. Kinase domains exist in
different conformations depending upon their activation state.
A number of key features have been identified that distinguish
active and inactive kinase conformations.40 The conserved
catalytic lysine residue (PvPKG Lys563), within the conserved
AxK signature sequence in β3, forms a salt bridge with the
catalytic glutamate (PvPKG Glu582) in the αC-helix in the
active “αCin”conformation and interacts with the α and β
phosphates of the bound ATP. In PIKs, a larger hydrophobic
residue is sometimes observed in the alanine position of the
AxK motif.
The C-terminal lobe forms the base of the ATP binding
pocket and contains the activation segment and the catalytic
loop, which play key roles in substrate binding and catalysis.
The side chain of the catalytic aspartate (PvPKG Asp675), at
the start of the activation segment within the conserved DFG
motif, points toward the ATP binding site in the active
“DFGin” conformation. There are generally one or more
phosphorylation sites within the activation segment (Thr688 in
PvPKG), and phosphorylation is required for activation in
some kinases. The APE motif (697APE699 in PvPKG), found at
the end of the activation segment, is highly conserved in ePKs.
This motif is not conserved in PIKs, which have a conserved
PFxLT motif at the end of the activation segment.41 The
catalytic loop contains the conserved HRD signature
(655YRD657 in PvPKG) with the catalytic aspartate thought to
assist in the transfer of the phosphoryl group from ATP to the
substrate.49,50 In the aPKs and PIKs, the arginine and histidine
are typically mirrored on the other side of the aspartate residue
(atypical DRH motif).41
■ SELECTING AN APPROPRIATE PLASMODIUM
KINASE FOR DRUG DISCOVERY
The ATP binding site, present in all kinases, is highly
druggable, and the structural requirements for designing
potent ATP-competitive kinase inhibitors are well understood
(Figure 3). This, together with the large number of
Plasmodium kinases that have been identified as genetically
essential for parasite survival,51,52 results in a long list of
potential kinase targets that could form the basis of target-
focused antimalarial drug discovery programs. However, not all
Figure 4. Integration of phenotypic- and target-based malaria drug discovery approaches. DEL, DNA-encoded libraries; TCP, target product
profile; MoR, mechanism of resistance; MoA, mechanism of action; cKD, conditional knockdown.
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of these kinases are likely to be good targets. In this section, we
discuss the different features that may determine whether or
not a particular kinase will be a good drug target. This is based
on criteria used to evaluate drug targets in infectious
diseases53−55 with a focus on kinases. This includes a
discussion of: (1) the essentiality and vulnerability across
different stages of the parasite life cycle; (2) druggability and
mode of inhibition; (3) conservation across Plasmodium
species and potential for pan-species activity; (4) homology
with human kinases and the potential for selectivity; (5) stage
specificity, speed of parasite killing, and potential to fulfill TCP
requirements; (6) a propensity for resistance; (7) the
availability of target-based assays; (8) the availability of
structural information. Target-based drug discovery programs
are most productive when they are closely integrated with
phenotypic approaches, allowing for phenotypic and in vivo
validation of the putative target as early as possible (Figure 4).
Fortunately, in the case of malaria, there are good cellular
models (subject to pharmacokinetic factors) and animal
models of infection. However, the ultimate validation of any
drug target is through the clinic, providing definitive evidence
that a compound inhibiting a specific molecular target is
capable of curing disease.
Essentiality and Vulnerability Across Different Stages
of the Parasite Life Cycle. Cabrera and colleagues have
previously discussed the four levels of target validation within
the context of Plasmodium kinases.14 For a kinase to be
exploitable for drug discovery, it must first be confirmed as
essential for parasite survival: i.e., the inhibition of the kinase
results in parasite death. This can be achieved through genetic
validation, chemical validation, or a combination of both.
Genetic validation51,52 can be achieved through a number of
approaches including: classical gene knockout by homologous
recombination or more recently by CRISPR-cas9 gene editing
(reviewed by Lee et al.56). The inability to knockout a specific
gene can provide indirect evidence that the gene is essential. A
variety of conditional knockdown (cKD) systems are now
available to interrogate target essentiality, vulnerability, and
function in Plasmodium. Target vulnerability refers to the
duration and extent to which the levels or activity of the target
need to be reduced to achieve parasite death. cKD approaches
allow the endogenous levels of specific proteins within
parasites to be depleted without being entirely ablated. cKD
lines are also increasingly used to confirm that compounds
remain on-target in the whole cell environment and thus
provide an important route for chemical validation. Cell lines
where targets of interest have been depleted can also be used in
high-throughput screening to rapidly identify chemical matter
capable of inhibiting the target within parasites. However, the
gold standard for genetic validation of drug targets in
Plasmodium remains the generation of conditional knockout
(cKO) lines using DiCre recombinase,57 FKBP-destabilization
Figure 5. Examples of Plasmodium kinase inhibitors. (A) PI4K inhibitors, (B) PKG inhibitors, and (C) CLK3 inhibitor.
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domains,58 glmS ribozyme,59 or other similar systems. Here,
endogenous genes can be removed and replaced by versions of
the target that can be switched on or off, allowing their role in
parasite survival to be definitively established. These
approaches can also provide an early and important indication
of the speed of cell killing associated with a specific target.
There are many examples where gene knockout/disruption
studies have yielded conflicting results (http://phenoplasm.
org/) even when carried out in the same Plasmodium species.
For example, conflicting results for tyrosine kinase-like 3
(TKL3) have been reported in both P. falciparum
(PF3D7_1349300) and P. berghei (PBANKA_1362100).
Reverse genetics studies in P. falciparum demonstrated that
TKL3 is likely essential for blood-stage schizogony.51,60 In
contrast, subsequent data from a piggyBac insertion muta-
genesis screen in P. falciparum suggests that TKL3 is
dispensable.30 Similarly, conflicting results have been reported
in P. berghei.52,61 While the reasons for these discrepancies
remain unclear, in a more recent study, a P. falciparum TKL3
cKD line showed only minor growth defects, corroborating the
finding that TKL3 is nonessential for asexual blood-stage
development in P. falciparum.62 It is important to note that
compensatory mechanisms activated due to reduced levels of
the target or reduced activity of a target may not be evident in
gene knockout studies and may also differ from compensatory
mechanisms activated during chemical inhibition of the target.
Many proteins have more than one function, including
important structural functions. Knocking out a gene entirely
will remove all of these functions of the corresponding protein,
and it will not be immediately clear which function is
responsible for killing the parasite. It should be noted,
however, that gene knockout strategies correspond to 100%
inhibition of a specific target. It is extremely challenging to
achieve this level of inhibition pharmacologically, particularly
for any extended period of time. Indeed, the lower the
percentage inhibition required to elicit a pharmacological
response, the better it is. Collectively, these issues illustrate the
difficulty in validating drug targets and highlight the need for
multiple complementary approaches to confirm the essentiality
of any given target.
Chemical validation is an alternate approach to validate
molecular targets. This requires development of a compound
that is highly selective for the target of interest;63 if this is
achieved, then it should be possible to obtain a direct
correlation between inhibition of the enzyme and parasite
death. However, it is challenging to develop a completely
selective inhibitor of a kinase, owing to the highly conserved
structural features of many kinases. Indeed, many human
kinase inhibitors are clinically efficacious precisely because they
inhibit more than one kinase.40 Target deconvolution studies
for compounds developed phenotypically can also lead to the
validation of novel molecular targets; for instance, PI4KIIIβ
was shown to be the primary target of KDU69164 and
MMV390048, now in clinical trials (Figure 5).8,9
Chemogenetics approaches provide an alternative method
for the chemical validation of kinases, whereby key active site
residues are mutated, altering the sensitivity of the mutated
kinase to a specific inhibitor. For example, in the “bump and
hole” approach developed by Shokat and co-workers,47,65 the
ATP binding site is made larger by genetically engineering in a
small gatekeeper residue, thus opening up the binding pocket
and allowing very selective inhibitors to be designed. Again,
this approach can be utilized to probe the physiological
function of an individual protein kinase.
Druggability and Mode of Inhibition. A key advantage
of targeting kinases for malaria drug discovery is that they are a
known druggable target class. There are a number of different
types of inhibitors of protein kinases with different ways of
binding.40,66,67
• Type I: ATP site targeting active form (DFG-in)
• Type I1/2: ATP site targeting inactive form (DFG-in)
• Type II: ATP site targeting inactive form (DFG-out)
• Type III: allosteric (binding to a cleft between the large
and small lobes but not the ATP binding site)
• Type IV: allosteric
• Type V: binds in at least two different parts of the active
site
• Type VI: covalent
The multiple different binding modes of inhibitors may offer
alternative drug discovery strategies to inhibit protein kinases.
This may be important in deriving selectivity or appropriate
physicochemical properties of compounds. Similarly, different
inhibitor binding modes also apply to PIKs, although the range
of binding modes observed in high-resolution structures is
more limited.68 Most published inhibitors of human kinases
bind to the highly druggable ATP binding site and have the
typical donor−acceptor−(donor) motif for binding to the
hinge. Binding interactions are well understood for compounds
that bind in this site. While the most common scaffolds bind to
multiple different kinase targets, many are more selective,
preferentially binding to specific kinase families.69 Despite
overall structural similarity, the shape of the ATP binding site
in aPKs and PIKs differs significantly from ePKs. PIK
inhibitors typically exploit unique interactions in the so-called
affinity and/or selectivity pockets.68,70 Interactions with the
affinity pocket are available due to the unique side chain
orientation of a residue at the start of β-sheet 4, toward the
binding site, as well as the orientation of the gatekeeper
residue, which typically blocks interactions with this back
pocket in ePKs. Furthermore, the unique composition of
residues in the P-loop of the PIKs results in the specificity
pocket being occupied by propeller-shaped inhibitors, which
are less flat than typical kinase inhibitors. Hinge-binding
scaffolds are typically very flat, and many have low solubility,
providing an additional challenge to compound development.
Ideally, an antimalarial will be in BCS (Biopharmaceutics
Classification System) Class I (high solubility and high
permeability).
A key issue with developing compounds for the treatment of
malaria is that TCPs dictate antimalarials must have a
sufficiently long half-life to facilitate single dose treatment
regimens. This usually requires compounds to have a suitable
balance of low clearance and high volume of distribution. It is
important that these features are built into a molecule during
the optimization process.
Conservation across Plasmodium Species: Pan-Spe-
cies Activity. Essentiality and structural conservation across
different human pathogenic Plasmodium species are important
to ensure that compounds will have pan-species activity. This is
an important consideration for clinical use in the field.
Generally, activity is only tested against one or two Plasmodium
kinase orthologues in vitro. In addition, many experimental
models rely on Plasmodium species that cause infection in
animals with the assumption that the targets are conserved.
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While ATP binding sites are typically highly conserved
between species, small structural differences in the kinase
domain may affect the potency in a compound specific
manner. Furthermore, allosteric sites may be more poorly
conserved. For example, the PfPI4KIIIβ and PvPI4KIIIβ have
an overall sequence identity of only 58%; however, their kinase
domains are highly homologous sharing 97% sequence
identity, and the residues making up the ATP binding site
are predicted to be identical.
Plasmodium and Human Kinases: Selectivity. A key
issue in developing kinase inhibitors for malaria is selectivity
over human kinases to prevent toxicity. There are relatively
small differences in the ATP binding sites of different kinases,
both Plasmodium and human. Therefore, it is always important
to, where possible, identify the closest human homologues for
counterscreening. Screening key compounds against a panel of
human kinases is important to highlight any significant
inhibition likely to cause toxicity to the host. This is a costly
screen, so only a few compounds can be screened against a
whole panel. However, if several human kinases are identified
as potential “anti-targets”, it is much more feasible to
counterscreen against those on a regular basis.
It is often very challenging to design compounds that are
selective for a Plasmodium kinase target relative to human
kinases at the outset of a project. However, if one or two
human kinases are specifically inhibited, then designing in
selectivity for the Plasmodium kinase is much more feasible.
The best starting point is one with no significant activity
against human kinases. It must also be noted that, even where
there is a direct human homologue to a pathogen target, it is
still possible to obtain compounds with a high degree of
selectivity; an example inhibitor developed against Leishmania
CRK3.71 Development of selective inhibitors capable of
targeting the parasite enzyme and not its human homologue
can be greatly facilitated by structure-based approaches.
Furthermore, there are examples of human ATP-competitive
kinase inhibitors that have been developed to specifically
inhibit only one isoform of several very closely related human
kinases. For example, both pan-PI3K class I inhibitors and
inhibitors that display selectivity for each of the individual
PI3K class I isoforms have been developed.25,70 This
demonstrates that selectivity can be obtained even in the
case of highly homologous ATP binding pockets. Selective
kinase inhibitors typically exploit nonconserved regions on the
periphery of the ATP binding site or subtle differences in the
accessibility, flexibility, and/or conformation of subpockets
adjoining the ATP site. While high resolution inhibitor-bound
structures can often be used to rationalize selectivity, many of
these isoform specific binding features may only become
apparent after a selective inhibitor is identified and an
inhibitor-bound structure is elucidated (e.g., the so-called
“specificity pocket” in PI3K isoforms that opens upon binding
of propeller-shaped inhibitors).70 In many cases, even where
structural information is available, key aspects of selectivity
remain unclear.
The determination of the selectivity window necessary to
mitigate the toxicity risk due to human kinase off-target activity
can be challenging. In vitro kinase inhibition data in the form of
IC50 values can provide a good indication of selectivity, but it is
important to note that these values are ATP concentration
dependent. The determination of the inhibitory constant (Ki)
more accurately predicts relative binding affinity. However,
differences in the Km ATP, ATP concentrations, and drug
exposure at target sites (inside different parasite compartments
at different life-cycle stages) and off-target sites (different
human cells/cellular compartments) may further confound off-
target activity predictions.72 In addition to selectivity based on
inhibition of the enzyme (Ki Plasmodium kinase/Ki human
kinase), there is also selectivity based on biological function. In
this case, inhibition of the enzyme in one species can have a
much more profound effect on the cellular growth than
inhibition of the same enzyme in another species. Furthermore,
the relatively short duration of malaria treatment may mitigate
toxicity that would otherwise be observed in the case of a high
dose, long-term treatment for chronic diseases such as cancer.
An attractive strategy to find very selective kinase inhibitors
is to target an allosteric pocket remote from the ATP binding
pocket. Allosteric pockets are usually specific to a particular
enzyme. Thus, an allosteric pocket in a malaria kinase is
unlikely to be found in any human kinases. A caveat is that
allosteric pockets may have a greater propensity to mutate than
highly conserved active site residues, and this may lead to an
increased resistance potential for drugs targeting these pockets.
Allosteric inhibitors do not need to compete with high cellular
levels of ATP. Another approach to develop selective inhibitors
would be to use a covalent inhibitor that targets a nucleophilic
residue in the active site/allosteric pocket of the Plasmodium
enzyme that is absent in the human orthologue(s).
Stage Specificity, Rate of Action, and Potential to
Fulfill TCP. Different kinases are expressed at different life-
cycle stages.15 It is important to understand at what stage the
kinase of interest is expressed and its vulnerability to inhibition
at each stage. The ideal scenario is that a kinase is essential
across multiple life-cycle stages. Targeting a kinase essential to
the liver, asexual blood, and the gametocyte or mosquito stages
of the life cycle has the potential to deliver an antimalarial with
prophylactic, curative, and transmission-blocking activity.
Ideally, the inhibition of a kinase leads to a fast rate of kill
of the blood stage form of Plasmodium, or if it has a moderate/
slow rate of kill, this occurs on multiple life-cycle stages. The
rate of kill can be measured in vitro using the parasite reduction
ratio (PRR) assay,73 in vivo using the SCID mouse model, and
ultimately in clinical studies in humans.
Propensity for Resistance. Resistance is a key challenge
for anti-infectives in general but particularly for antimalarials.
There are a number of different mechanisms by which
resistance can emerge in pathogens. These can include the
following: mutations in the target enzyme; amplification of the
target enzyme; increased efflux of the compound from the
parasite due to amplification of the parasites’ efflux trans-
porters; reduced uptake of the compound due to down-
regulation of parasite importers; upregulation of bypass
pathways; increased uptake of key intermediates from the
human host; direct metabolism of the inhibitor. In
Plasmodium, drug resistance is most commonly driven by
mutation rather than amplification, and in vitro drug resistance
selections followed by whole genome sequencing are regularly
used to assist in target identification and to estimate the
resistance potential of development compounds. It is unclear if
resistance is an intrinsic feature of specific targets, inhibitors, or
both. However, some indication that resistance is difficult to
obtain is valuable in validating a given target. First, there
should be no significant cross-resistance to existing antima-
larials, which can be examined by screening against parasite
strains resistant to existing antimalarial. Second, it is possible to
measure the minimum inoculum for resistance (MIR).74
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Compounds with a MIR of <105 are considered high risk,
while those with a MIR of >107 are much lower risk. Some
examples of clinically used compounds are reported by Ding et
al.74 The MIR depends on the Plasmodium cell line used. Fold
increases in EC50 values of resistant clones relative to sensitive
parasites and the associated fitness cost to the parasite are also
considered when assessing resistance potential.74 Another
important feature is the level of conservation of the active site
across different Plasmodium species and clinical isolates. This
information can be used to assess the risk of pre-existing,
naturally occurring resistance once the drug is used widely in
the field.
Availability of Target-Based Assays. A variety of
different assay formats have been developed for the study of
kinases with many amenable to high-throughput screening.75,76
Radiometric incorporation assays utilizing radioisotope labeled
γ-ATP are considered the gold standard. Nonradiometric assay
formats include universal ADP-detection assays typically
utilizing either coupled enzyme reactions (e.g., Promega
ADP-Glo Kinase Assay, DiscoverX ADP Hunter, and ADP
Quest Assays) or antibody-based methods (e.g., Bellbrook
Laboratories Transcreener ADP2 Fluorescent Polarization, and
Fluorescent Intensity Kinase Assays) to quantify ADP
formation. Other methods detect the phosphorylation of
labeled substrates and include FRET-based methods (e.g.,
Cisbio KinEASE TR-FRET kits) and mobility shift assays (e.g.,
Caliper Life Sciences microfluidic chip-based assays). High-
throughput mass spectrometry detection methods (e.g.,
Agilent RapidFire Mass spectrometry platform) allow for
sensitive and direct quantitative detection of native substrates
and products. Despite this, there are still a number of
challenges in developing a robust assay. First, soluble,
enzymatically active protein must be readily generated by
recombinant expression. The genome of Plasmodium is
extremely AT rich, particularly in P. falciparum, making
recombinant expression in bacterial and eukaryotic expression
systems particularly challenging. This issue can be circum-
vented if Plasmodium expression constructs are codon-
optimized for the desired expression system prior to
expression. Some Plasmodium proteins have large inserts,
consisting of low complexity regions of amino acid
homorepeats, which are particularly prevalent in P. falciparum.
These repeated sequences again make recombinant expression
difficult, and in some cases, it is necessary to use a closely
related orthologue from another Plasmodium species more
conducive to expression and subsequent purification. Second,
many kinases are activated by phosphorylation or other post-
translational modifications and may not be isolated in their
active form. Third, it is necessary to find a substrate protein or
peptide for the kinase to support assay development. This can
often prove challenging where there is no knowledge of the
physiological function of the kinase or it is natural substrate.
Structural Biology. Structural information surrounding
targets of interest can be extremely valuable in compound
optimization to drive both potency improvement and
selectivity against a human orthologue. This again is dependent
upon recombinant expression of soluble and stable protein.
Advances in X-ray crystallography and cryo-electron micros-
copy now enable high-resolution structures to be generated for
challenging proteins. High-throughput cloning and protein
production strategies enable the rapid assessment of multiple
engineered protein constructs for structural biology.77,78 In
addition, antibodies/nanobodies can be used as chaperones for
structure determination to improve sample homogeneity/aid
crystallization and/or stabilize protein targets in a desired
conformation.
CDPK1: An Example. Many of the challenges associated
with target selection and validation have been highlighted by
Plasmodium CDPK1, one of the first Plasmodium kinases
explored extensively as a drug target. CDPK1 initially appeared
to fulfill many of the key requirements of a promising target
including (1) genetic essentiality for asexual blood-stage
development and transmission based on unsuccessful attempts
to knockout cdpk1, (2) druggability, (3) conservation across
Plasmodium species, (4) unique structural features with no
orthologue in humans, and (5) a small gatekeeper residue that
could be exploited for selectivity.52,79,80 Recombinant
expression of Plasmodium CDPK1, development of a
biochemical assay suitable for high-throughput screening, and
a high-resolution crystal structure of PbCDPK1 (PDB 3Q5I)
provided the key tools to drive target-based drug discovery
efforts.80,81
Despite these promising features and the identification of
potent CDPK1 inhibitors with good antiplasmodium activity,
the validity of CDPK1 as a drug target for TCP1 has been
brought into question. Follow up medicinal chemistry efforts
showed a poor correlation between CDPK1 enzyme inhibition
data and antiplasmodium activity, suggesting that other targets
might be involved and hindering phenotypic target valida-
tion.82 Despite multiple, unsuccessful attempts to knockout or
disrupt cdpk1 in P. falciparum, Jebiwott et al. successfully
disrupted cdpk1 in P. berghei.83 Subsequent studies, utilizing
engineered parasites with gatekeeper mutations, demonstrated
that PKG-mediated pathways can compensate for reduced
CDPK1 activity,84,85 consistent with the observation that the
conditional knockdown of CDPK1 in P. falciparum shows no
significant phenotype.62 In an elegant study, Green et al.
showed that the imidazopyridazine series that potently inhibits
PfCDPK1 could be split into two classes on the basis of the
mode of action in asexual blood-stage parasites with the
primary target being either PKG or heat shock protein 90
(Hsp90) rather than CDPK1.86 CDPK1 has been shown to be
essential for transmission, so the inhibition of CDPK1 may still
be a good strategy for TCP5.52,87 This example highlights the
importance of phenotypic validation, the complexity of
compensatory mechanisms, and the potential role of multiple
targets in antiplasmodium activity. This also serves as a
reminder that small structural modifications within the same
chemical series can lead to a change in mode of action and/or
implicate additional targets, particularly when the target is part
of a large multigene family.
■ OPPORTUNITY FOR POLYPHARMACOLOGY
Many drugs are known to inhibit more than one molecular
target at pharmacological doses.88 This could be perceived as
an advantage for an anti-infective agent, for several reasons, if it
is active against more than one of the pathogen’s enzymes.
First, if both enzymes are essential, then this can limit the
potential for resistance to emerge, since the likelihood of a
resistance-generating mutation spontaneously occurring in two
independent targets at the same time in one parasite is
extremely low.89 This is illustrated in bacteria, where
compounds such as the fluoroquinolones inhibit both gyrase
and topoisomerase II.90 Second, compounds demonstrating
polypharmacology have the potential to increase the efficacy.
Targeting multiple enzymes within the same or related
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pathways may result in synergistic effects, as seen with
dihydropteroate synthase and dihydrofolate reductase inhib-
itors with both acting on the folate metabolism.91,92 Synergism
potentially allows improved efficacy at a given dose. However,
one potential risk is if resistance occurs to one of the agents
and the other is dosed sub-therapeutically, then treatment with
the combination could fail. Third, polypharmacology will have
the added advantage of benefiting patients by minimizing the
pill burden and cost associated with combination drug
regimens, which currently requires two or more small
molecules that inhibit different single targets to be combined.
It is noteworthy that building the appropriate combination
drug regimens takes time as well as resources and a significant
amount of data. If the compounds become too broad in the
kinases they inhibit, there is a concomitant increased risk of the
inhibition of critical human kinases.
There are several useful tools that can be utilized to identify
secondary targets of kinase inhibitors and their impact on
antiplasmodium activity. Chemoproteomic approaches, such as
Kinobead experiments, principally used for target identification
and selectivity profiling of ATP-competitive kinase inhibitors,
regularly identify multiple Plasmodium kinase targets in
addition to the primary target.62,93,94 This information is
valuable for identifying scaffolds and kinase partners that could
form the basis for the design of multi-kinase inhibitors. A
change in rate of cell killing or stage specificity may indicate
that additional targets are implicated or that there has been a
change in the primary mode of action.94 Furthermore, the
secondary targets may provide valuable information with
regards to related human kinases that may mediate off-target
effects. Omics approaches, such as transcriptomics and
phosphoproteomics profiling, can provide a more complete
picture of the effect of compounds on multiple pathways
within the parasite. Coupled with genetic approaches,
comparative omics studies can be used to distinguish “on-
target” effects of inhibitors from those resulting from
additional/secondary targets.95−97
There are numerous examples of Plasmodium kinase
inhibitors reported to inhibit more than one kinase from
different kinase families32,93,94 as well as closely related
analogues shown to primarily act through different essential
kinases.64,86 These compounds could serve as starting points
for the design of dual or multikinase inhibitors. We anticipate
that, as more data sets are generated showing the benefits of
targeting multiple Plasmodium kinases, a so-called “magic
shotgun” approach rather than a “magic bullet” approach,98 in
which drugs are purposefully designed to interact selectively
with multiple molecular targets, may gain traction.
■ EXAMPLES OF KINASES BEING TARGETED IN
MALARIA
Several Plasmodium kinases are being advanced and show
promise. Our previous review covered some of this work.14
Here, we give an update on 3 chemically validated kinases that
have been demonstrated to be essential to multiple stages of
the Plasmodium life cycle and look exciting from a malaria drug
discovery perspective (Table 1).
PI4KIIIβ. PI4KIIIβ was first reported as a promising
antimalarial target in 2013 after it was identified as the
primary target of novel imidazopyrazine/pyridine compounds
(e.g., KDU691, Figure 5A) displaying potent prophylactic
liver-stage, asexual blood-stage, and transmission-blocking
antiplasmodium activity in mouse models of malaria.64 Target
identification involved in vitro resistant selections that resulted
Table 1. Key Attributes of Three Promising Plasmodium Kinase Targets
aPI4K,8,9,64 phosphatidylinositol 4-kinase type III beta; PKG,62,99 cGMP-dependent protein kinase; CLK3,97 cyclin-dependent-like kinase 3. bSee
Figure 5 for chemical structures of tool compounds. cTool compound/s showed activity in assays testing for asexual blood-stage (ASB),
transmission-blocking (T), and prophylactic liver-stage (L) antiplasmodium activity. dClosest human orthologue (percentage shared sequence
identity); PI4KIIIβ, phosphatidylinositol 4-kinase type III beta (UniProt Q9UBF8); PRKG1/2, protein kinase cGMP-dependent 1 and 2 (UniProt
Q13976 and Q13237); PRP4, pre-mRNA-processing factor 4 (UniProt Q13523). eBased on data from the in vitro parasite reduction ration assay.
fBased on the minimum inoculum of resistance (MIR) determined for tool compounds in in vitro drug-resistance selections and EC50 fold change
associated with resistance. gML10 or MMV030084 resistance selections did not identify PKG mutations. The continuous exposure of Dd2-B2
parasites to 3× EC50 of MMV030084 yielded resistant parasites with a T1268R mutation in tyrosine kinase-like protein 3 (TKL3;
PF3D7_1349300) that showed a 2.9-fold EC50 shift compared with the parental line. Continuous exposure of 10
9 Dd2-B2 TKL3 knockout
parasites did not result in parasite recrudescence. hcKD, conditional knockdown. iEngineered inhibitor-insensitive P. falciparum PKG T618Q
parasite line. jEngineered inhibitor-insensitive P. falciparum CLK3 G449P parasite line. kHigh-resolution structures of PfPKG (PDB ID: 5DYK)
and PvPKG (PDB IDs: 4RZ7, 5F0A, 5DYL, 5DZC, 5FET, 5EZR).
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in drug resistant P. falciparum lines with mutations in the
kinase domain of PI4KIIIβ and Rab11a, a small GTPase
known to interact with PI4KIIIβ in humans. To confirm the
role of these mutations in resistance, they were then
engineered into P. falciparum Dd2.64 Subsequent biochemical
assays using recombinantly expressed P. vivax PI4KIIIβ
confirmed that these inhibitors are potent ATP-competitive
inhibitors of Plasmodium PI4KIIIβ. These compounds were
not progressed, but PI4KIIIβ was subsequently identified as
the primary target for a very promising series of amino-
pyridines/pyrazines.8,100
The most advanced Plasmodium kinase inhibitor, the 2-
aminopyridine MMV390048 (Figure 5A), is currently in Phase
II clinical trials for the treatment of malaria targets PI4KIIIβ.8,9
Using a phenotypic-based approach, MMV390048 and other
related compounds were developed from whole cell screening
hits identified from a Soft Focus Kinase Library without prior
knowledge of their targets. Target identification studies,
including resistance selections in P. falciparum, chemo-
proteomic studies, and biochemical assays, all pointed to
PI4KIIIβ as the primary target. In addition, a good correlation
between in vitro antiplasmodium activity and enzyme
inhibitory potencies was observed for this series.8 More
recently, MMV390048 was reported to potently inhibit
PfPI3K in addition to PfPI4KIIIβ in vitro, but the contribution
of PfPI3K inhibition to compound efficacy is not yet known.32
MMV390048 displayed good in vitro selectivity for Plasmodium
PI4K with limited off-target activity against human kinases and
the potential to fulfill TCP1, TCP4, and TCP5, consistent with
the essential role of PI4KIIIβ in multiple stages of the life
cycle.8 MMV390048 showed a moderately slow rate of kill in
the in vitro PRR assay and a moderate rate of kill in vivo but a
fast killing profile in the clinic.
Pf PI4KIIIβ competitive inhibitors show a moderate
propensity for resistance in vitro with a MIR of 106−107.8,100
Nine different PI4KIIIβ single point mutations within the
kinase domain as well as PI4K copy number variations and a
single point mutation in Rab11a have been reported for
laboratory resistant lines generated against a range of PI4KIIIβ
inhibitors.8,64,100,101 These resistant lines displayed low to
moderate EC50 shifts (3- to 22-fold) with some PI4K
mutations showing compound specific effects. There is still
considerable interest in developing new PI4KIIIβ inhibitors
with distinct chemotypes as backups for MMV390048.
Further, several other chemotypes that inhibit Plasmodium
PI4K have been reported.101−104 While a structure of
Plasmodium PI4KIIIβ is yet to be elucidated, high-resolution
structures of human PI4KIIIβ (e.g., PDB 4D0L) are now
available,105,106 providing valuable information for under-
standing selectivity and a template from which to build a
PfPI4KIIIβ homology model.107 This coupled with enzyme
inhibition data and multiple inhibitor-bound structures of
related human PI3K proteins provides a wealth of valuable
information to optimize inhibitors for PfPI4KIIIβ potency and
selectivity.
PKG. Plasmodium PKG is a serine/threonine protein kinase
that plays an essential role in multiple stages of the parasite life
cycle. Plasmodium PKG, consisting of a kinase domain and
three active and one degenerate nucleotide binding domains,
shows significant divergence from mammalian PKGs, which
only have two cGMP-binding domains.108 The structure of
PKG has been studied in detail.45 Differences in the activation
mechanism and regulatory site specificity between Plasmodium
PKG and human PKGs have also been reported.109
Importantly, the inhibition of PKG utilizing small molecule
ATP-competitive inhibitors has been shown to result in
prophylactic liver stage, blood-stage, and transmission-blocking
antiplasmodium activity.62,99 Baker et al. provided an in vivo
proof-of-concept in a humanized mouse model of P. falciparum
infection, showing that oral dosing of ML10 (Figure 5B), the
lead compound from a imidazopyridine series of potent PKG
inhibitors, was able to clear parasites from the blood.99
Following phenotypic validation, a high-throughput target-
based biochemical screen of the GlaxoSmithKline (GSK) Full
Diversity Collection against recombinant PfPKG identified a
number of additional PKG inhibitor chemotypes with the
trisubstituted thiazoles (Figure 5B) identified as the most
promising scaffolds. These scaffolds have subsequently become
the subject of several medicinal chemistry programs.93,110
Additional kinase targets were implicated for a subset of
thiazoles that were shown to be fast acting in vitro, deviating
from the slow rate of kill typically observed for PKG
inhibitors.94 More recently, PKG was identified as the primary
target for the trisubstituted imidazole MMV030084 (Figure
5B) that shows potent antiplasmodium activity across the
parasite life cycle and structural similarity with PKG inhibitors
identified from the GSK Full Diversity Collection.62 In line
with the described roles of PKG, MMV030084 inhibited
hepatocyte invasion by sporozoites; merozoite egress from
asexual blood-stage schizonts, and male gamete exflagellation.
Resistance selections carried out with both MMV030084 and
the imidazopyridine ML10 did not lead to mutations in PKG,
suggesting that PKG is a target with a low propensity for
resistance.62,99 In the case of MMV030084, a continuous
exposure of the drug resulted in resistant parasites with a
T1268R mutation in tyrosine kinase-like protein 3 (TKL3,
PF3D7_1349300) conferring a 2.9-fold EC50 shift compared
with the parental line.62 The molecular basis for TLK3-
mediated resistance is not clear, and it is yet to be determined
if this TKL3 mutation results in cross-resistance to other
compounds targeting PKG. In addition to PKG cKD and cKO
approaches, a chemogenetics approach making use of
engineered inhibitor-insensitive parasite lines containing a
gatekeeper mutation has served as a useful tool to demonstrate
on-target whole cell activity and study PKG func-
tion.96,99,111−114 On the basis of the previously reported series
targeting PfPKG, very significant PKG inhibition appears to be
required for good whole cell activity with a difference of
roughly 2 orders of magnitude typically observed between
PKG IC50 values (generated in the presence of ATP at a
concentration equal to the Km of ∼20 μM) and P. falciparum
EC50 values.
Unlike both human PKGs and many other human serine/
threonine protein kinases, Plasmodium PKG has a small
gatekeeper residue, allowing inhibitors access to the back
pocket. Even though reported Plasmodium PKG inhibitors
exploit this back pocket, providing a degree of selectivity,
human kinase off-target selectivity remains a key concern for
drug development. The mechanism of in vitro allosteric
inhibition of PfPKG using cGMP analogues has recently
been described.115 However, allosteric PfPKG inhibitors with
potent antiplasmodium activity are yet to be reported.
While PKG inhibitors have been shown to be slow acting in
the in vitro PRR assay,94,99 PKG as a target has other favorable
properties including the potential to deliver antimalarials with
multistage activity that have a low propensity to generate
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resistance. It is also still not yet clear how in vitro speed of kill
data for PKG inhibitors will translate into the clinic. The
availability of inhibitor-bound high-resolution structures,
biochemical assays suitable for high-throughput screening,
and chemogenetic tools to test for on-target whole cell activity
makes Plasmodium PKG an attractive target for structure-based
drug design.
CLK3. P. falciparum cyclin-dependent-like kinase 3 (CLK3,
PF3D7_1114700) has emerged as a promising drug target with
the potential to yield antimalarials with multistage activity.97
TCMDC-135051 (Figure 5C), a CLK3 inhibitor displaying
liver stage prophylactic, asexual blood-stage antiplasmodium
activity and transmission reducing potential, has recently been
identified from a target-based screen.97 CLK3 is one of four
CLKs in Plasmodium.15 CLKs 1−3 have been shown to be
genetically essential for asexual blood-stage develop-
ment.30,52,96,116 In humans and other eukaryotes, CLKs and
the closely related serine/arginine protein kinase (SRPK)
family belonging to the CMGC ePK group are dual specificity
kinases that phosphorylate serine/arginine-rich (SR) proteins,
playing key roles in regulating mRNA processing. Given the
demonstrated genetic essentiality of CLKs in the asexual blood
stage, their proposed role in regulating mRNA splicing, and
high conservation across Plasmodium species, it was hypothe-
sized that these kinases would play crucial roles in all stages of
the parasite life cycle, making them attractive targets requiring
chemical validation.94,117 On the basis of this premise, CLK1
and CLK3 were recombinantly expressed and biochemical
assays suitable for high-throughput screening were estab-
lished.97 A screen of nearly 30 000 compounds composed of
several kinase-focused libraries identified CLK1 and CLK3
selective small molecule inhibitors in addition to inhibitors
targeting both CLK1 and CLK3. In vitro resistance selections,
using CLK3 selective inhibitor TCMDC-135051, resulted in
point mutations within CLK3 and putative RNA processing
protein PfUSP39 (PF3D7_1317000) giving rise to in a 4- to
11-fold shift in EC50. On target whole cell activity for
TCMDC-135051 was confirmed using a chemogenetics
approach, phenotypically validating CLK3 as a target. The
chemogenetics approach relied on mutating a CLK3 specific
active site residue to its CLK1 counterpart (G449P), resulting
in a CLK3 variant and corresponding parasite line with
reduced sensitivity to TCMDC-135051. Furthermore,
TCMDC-135051 showed rapid killing in in vitro PRR assays
and selectivity for Plasmodium CLK3 relative to its human
ortholog PRPF4B and closely related human CLK1. Selectivity
based on a panel of representative human kinases is yet to be
reported. A transcriptome analysis study revealed that CLK3
inhibition resulted in the downregulation of more than 400
genes thought to be essential to parasite survival, most of
which contain introns, consistent with the role of CLK3 in
regulating RNA splicing. Initial medicinal chemistry optimiza-
tion efforts focused on TCMDC-135051 have been
reported,118 and we anticipate new target-based programs
focused on CLK3 and other promising CLKs (e.g., CLK2),
including structural biology efforts, to follow.
■ COMMENT
In summary, kinases are promising drug targets that have been
relatively poorly explored in malaria, compared to the effort on
human kinases. There is a large amount of literature available
to guide the design of inhibitors for this family of enzymes.
Furthermore, many compounds have been developed in
human kinase inhibitor programs, some of which could act
as leads for antimalarial drug discovery. The obtainment of
selectivity over human kinases can be very challenging and
chemistry resource intensive, but it is worth noting that not all
off-target activity will necessarily lead to toxicity.
Many factors, in addition to genetic essentiality, need to be
considered when selecting a kinase to target. Target-based drug
discovery efforts need to be closely integrated with phenotypic
approaches so that phenotypic validation can be achieved at an
early stage. Phenotypic whole cell screening of kinase-focused
libraries followed by target deconvolution studies is a good way
to identify promising kinase−inhibitor pairs. Kinase-specific
chemoproteomic approaches, coupled with advances in
genome editing technologies for Plasmodium, have provided
a powerful set of tools to assist in target identification and
validation.
The development of a panel of in vitro Plasmodium kinase
assays together with more structural information would greatly
facilitate drug discovery. Target-based screens using purified
kinases also have the potential to identify non-ATP
competitive modes of action that may overcome some of the
challenges related to selectivity. This also may circumvent the
problem that few ATP-competitive inhibitors are BCS Class 1.
The potential for resistance needs to be monitored, particularly
due to the high rates of clinical resistance seen for kinase
inhibitors in cancer. Given the structural similarity between
kinases, specifically designing in polypharmacology is a very
attractive proposition119 but is still very much in its infancy.
In this Perspective, we have highlighted the many factors
that require consideration when prioritizing a kinase to target.
While the absence of a known human homologue may be an
attractive feature, the conserved nature of the ATP site across
this large superfamily of enzymes makes it difficult to predict
potential kinase off-targets (or adverse effects caused by off-
target activity), and the obtainment of selectivity may still be
challenging. On the other hand, Plasmodium kinases with
human orthologues may have specific features that allow for
the selective inhibition of the Plasmodium enzyme. It is difficult
to say if any specific class of kinases represents a superior target
class for the development of antimalarials. However,
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